Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H30O3 |
| Molecular Weight | 318.4504 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@]12CCC[C@](C)([C@H]1CC[C@@]34CC(=C)[C@@](O)(C3)CC[C@@H]24)C(O)=O
InChI
InChIKey=QFVOYBUQQBFCRH-VQSWZGCSSA-N
InChI=1S/C20H30O3/c1-13-11-19-9-5-14-17(2,7-4-8-18(14,3)16(21)22)15(19)6-10-20(13,23)12-19/h14-15,23H,1,4-12H2,2-3H3,(H,21,22)/t14-,15-,17+,18+,19+,20-/m0/s1
| Molecular Formula | C20H30O3 |
| Molecular Weight | 318.4504 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Stevioside, an abundant component of Stevia rebaudiana leaf, has become well-known for its intense sweetness (250-300 times sweeter than sucrose) and is used as a non-caloric sweetener in several countries. Steviol and isosteviol (metabolic components of stevioside) may offer therapeutic benefits, as they have anti-hyperglycemic, anti-hypertensive, anti-inflammatory, anti-tumor, anti-diarrheal, diuretic, and immunomodulatory actions. In the presence of 16.7 mM glucose both stevioside and steviol enhance insulin secretion from incubated islets in a dose-dependent manner (1 nM to 1 mM). Even though both
stevioside and steviol possess an insulinotropic/anti-hyperglycemic
effect, steviol is more potent than stevioside. Steviol is an inhibitor of hOAT1 and hOAT3 organic anion transporters. Human organic anion transporter hOAT1 belongs to a superfamily of organic anion transporters, which play critical roles in the body disposition of clinically important drugs including anti-HIV therapeutics, anti-tumor drugs, antibiotics, anti-hypertensives, and anti-inflammatories. Highly purified steviol glycosides have repeatedly received Generally Recognized As Safe (GRAS) status from the US Food and Drug Administration in the past (FDA).
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3201 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28887089 |
3.3 µM [EC50] | ||
Target ID: CHEMBL2364675 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28887089 |
63.7 µM [IC50] | ||
Target ID: CHEMBL3397 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28887089 |
49.1 µM [IC50] | ||
Target ID: CHEMBL3401 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28887089 |
|||
Target ID: CHEMBL1250410 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26407946 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Transmembrane transport of steviol glucuronide and its potential interaction with selected drugs and natural compounds. | 2015-12 |
|
| Stevia-derived compounds attenuate the toxic effects of ectopic lipid accumulation in the liver of obese mice: a transcriptomic and metabolomic study. | 2015-03 |
|
| Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. | 1991-01-01 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24518257
Mice: Experimental mice daily received steviol at doses of 40 and 200 mg/kg BW (10% of DMSO plus 90% of 0.9% normal saline) through an intraperitoneal
(i.p.) injection.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28887089
A statistically significant activation of PXR- and AHR-responsive constructs was found after treatment with steviol at the concentration of 30 uM. Steviol dose-dependently activated AHR in HepG2 cells transfected with pXRE-luc, with EC50 equal to 7.5 uM. In human intestinal CACO2 cells, steviol and stevioside (at 10 uM concentration, 48-hour treatment) upregulated expression of both CYP1A2 and CYP1B1 genes at mRNA level.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:44:21 GMT 2025
by
admin
on
Mon Mar 31 19:44:21 GMT 2025
|
| Record UNII |
4741LYX6RT
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID50897427
Created by
admin on Mon Mar 31 19:44:21 GMT 2025 , Edited by admin on Mon Mar 31 19:44:21 GMT 2025
|
PRIMARY | |||
|
471-80-7
Created by
admin on Mon Mar 31 19:44:21 GMT 2025 , Edited by admin on Mon Mar 31 19:44:21 GMT 2025
|
PRIMARY | |||
|
145011
Created by
admin on Mon Mar 31 19:44:21 GMT 2025 , Edited by admin on Mon Mar 31 19:44:21 GMT 2025
|
PRIMARY | |||
|
1363645
Created by
admin on Mon Mar 31 19:44:21 GMT 2025 , Edited by admin on Mon Mar 31 19:44:21 GMT 2025
|
PRIMARY | RxNorm | ||
|
m10208
Created by
admin on Mon Mar 31 19:44:21 GMT 2025 , Edited by admin on Mon Mar 31 19:44:21 GMT 2025
|
PRIMARY | Merck Index | ||
|
STEVIOL
Created by
admin on Mon Mar 31 19:44:21 GMT 2025 , Edited by admin on Mon Mar 31 19:44:21 GMT 2025
|
PRIMARY | |||
|
452967
Created by
admin on Mon Mar 31 19:44:21 GMT 2025 , Edited by admin on Mon Mar 31 19:44:21 GMT 2025
|
PRIMARY | |||
|
145024
Created by
admin on Mon Mar 31 19:44:21 GMT 2025 , Edited by admin on Mon Mar 31 19:44:21 GMT 2025
|
PRIMARY | |||
|
C012042
Created by
admin on Mon Mar 31 19:44:21 GMT 2025 , Edited by admin on Mon Mar 31 19:44:21 GMT 2025
|
PRIMARY | |||
|
226902
Created by
admin on Mon Mar 31 19:44:21 GMT 2025 , Edited by admin on Mon Mar 31 19:44:21 GMT 2025
|
PRIMARY | |||
|
4741LYX6RT
Created by
admin on Mon Mar 31 19:44:21 GMT 2025 , Edited by admin on Mon Mar 31 19:44:21 GMT 2025
|
PRIMARY | |||
|
4741LYX6RT
Created by
admin on Mon Mar 31 19:44:21 GMT 2025 , Edited by admin on Mon Mar 31 19:44:21 GMT 2025
|
PRIMARY |